Jefferies puts MannKind on hold

Jefferies & Co., Inc. analyst Adam Walsh rated MannKind Corp. at hold after the Technosphere Insulin (TI inhaled insulin) achieved a comparable increase in HbA1c, statistically significant weight reduction and pulmonary safety when compared to NovoLog. The analyst believes a TI partnership is the potential next key catalyst for the stock. Shares of the Valencia, Calif.-based biopharmaceutical company were up 11 cents, or 0.57%, at $19.39. (Nasdaq: MNKD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.